Showing 601 - 620 results of 1,139 for search '"Neuro-oncology"', query time: 0.11s Refine Results
  1. 601
  2. 602
  3. 603
  4. 604

    LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RA... by Cornelis M. van Tilburg, Lindsay B. Kilburn, Sébastien Perreault, Rene Schmidt, Amedeo A. Azizi, Ofelia Cruz-Martínez, Michal Zápotocký, Katrin Scheinemann, Antoinette Y. N. Schouten-van Meeteren, Astrid Sehested, Enrico Opocher, Pablo Hernáiz Driever, Shivaram Avula, David S. Ziegler, David Capper, Arend Koch, Felix Sahm, Jiaheng Qiu, Li-Pen Tsao, Samuel C. Blackman, Peter Manley, Till Milde, Ruth Witt, David T. W. Jones, Darren Hargrave, Olaf Witt

    Published 2024-01-01
    “…The type II RAF inhibitor, tovorafenib (formerly DAY101, TAK-580, MLN2480), has shown promising activity and good tolerability in patients with BRAF-altered pLGG in the phase 2 FIREFLY-1 study, with an objective response rate (ORR) per Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG) criteria of 67%. …”
    Get full text
    Article
  5. 605
  6. 606
  7. 607
  8. 608
  9. 609
  10. 610
  11. 611

    Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment by Víctor A. Arrieta, Crismita Dmello, Daniel J. McGrail, Daniel J. Brat, Catalina Lee-Chang, Amy B. Heimberger, Dhan Chand, Roger Stupp, Adam M. Sonabend

    Published 2023-01-01
    “…Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing great interest in the neuro-oncology community. While several reports show that subsets of patients with glioma exhibit durable responses to immunotherapy, the efficacy of this treatment has not been observed for unselected patient populations, preventing its broad clinical implementation for gliomas and glioblastoma (GBM). …”
    Get full text
    Article
  12. 612
  13. 613
  14. 614
  15. 615

    The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression by Filippo Torrisi, Cristiana Alberghina, Simona D’Aprile, Anna M. Pavone, Lucia Longhitano, Sebastiano Giallongo, Daniele Tibullo, Michelino Di Rosa, Agata Zappalà, Francesco P. Cammarata, Giorgio Russo, Massimo Ippolito, Giacomo Cuttone, Giovanni Li Volti, Nunzio Vicario, Rosalba Parenti

    Published 2022-03-01
    “…Among the adult-type diffuse gliomas, glioblastoma represents most primary brain tumors in the neuro-oncology practice of adults. Despite massive efforts in the field of neuro-oncology diagnostics to ensure a proper taxonomy, the identification of glioblastoma-tumor subtypes is not accompanied by personalized therapies, and no improvements in terms of overall survival have been achieved so far, confirming the existence of open and unresolved issues. …”
    Get full text
    Article
  16. 616
  17. 617
  18. 618
  19. 619
  20. 620